Navigation Links
Sinovac Requests Extension for Annual Shareholders Meeting
Date:12/13/2007

BEIJING, Dec. 13 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that it has notified the Listing Qualifications Department at the American Stock Exchange that the Company will defer its 2007 annual stockholders meeting to no later than April 30, 2008.

The Company originally scheduled its 2007 annual stockholders meeting in August 2007. The meeting was postponed because the Company could not form the necessary quorum, which is 50% of the outstanding shares based on the Company's by-laws. The Company does not believe that it will be able to form the necessary quorum to hold the 2007 annual meeting by year-end, and it is continuing to evaluate different options as an Antigua corporation and a foreign private issuer.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) and Anflu(TM) (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, and Japanese encephalitis. Additional information about Sinovac is available on its website, http://www.sinovac.com. To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
3. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
4. Sysmex America Awarded MedAssets Supply Chain Systems Hematology Contract Extension
5. AMDL Announces Filing of Extension on Third Quarter 2007 Form 10-QSB
6. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
7. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
8. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
9. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
10. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
11. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... 19, 2014 A Geisinger researcher on a ... a Centers for Disease Control and Prevention (CDC) award ... health concern. Joseph Boscarino , Ph.D. ... a team of researchers nominated for the Centers for ... Award for Data Methods and Study Design. ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership ... production from bioactive small molecules. Based on ... enables convenient and timely assessment of critical metabolite ... President of Commercial Operations, Christian Darabant, “the value ... can be measured directly by comparison with the ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... Madison Wis - The University of Wisconsin Medical ... integration of the Medical Foundation's clinical data and to ... The foundation has choosen QDX Platform V Integration ... vertical solutions company based in Englewood, Colorado. , ,The ...
... an ATM and point-of-sale (POS) processing business, said ... increase more than 57% in 2003 to 223 million ... was tremendous and makes ACCEL/Exchange one of the nation's ... President of Products and Networks for Fiserv EFT/CNS. "In ...
... Madison, Wis. -- OpGen, Inc. , a provider of ... optical mapping study of a deadly type of brain tumor, ... the Hermelin Brain Tumor Center and professor of ... founder of OpGen, David Schwartz . , ,Optical mapping, ...
Cached Biology Technology:UW Medical Foundation Integrates Medical Records 2OpGen joins UW, Henry Ford Heath in Improving Brain Tumor Treatment 2
(Date:8/20/2014)... salty aroma of sunscreen and seawater signals a relaxing ... that the idyllic beach vacation comes with an environmental ... into the sea, they can become toxic to some ... course for many other marine animals. Their study appears ... . , Antonio Tovar-Sanchez and David Snchez-Quiles point out ...
(Date:8/20/2014)... gene therapy developed by researchers at the University of ... mice from a life-threatening heart condition caused by muscular ... said Yi Lai, Ph.D., the leading author of the ... of Medicine,s Department of Molecular Microbiology and Immunology. "This ... could lead to a treatment for people with this ...
(Date:8/20/2014)... , Aug. 20, 2014  The second annual ... in Tampa, Florida on ... with Steven Rahman, Director, Technology and Strategy at Samsung, ... Experian. The theme of this year,s event is ... "Biometrics UnPlugged: Mobility at the ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... soil samples indicates that a group of microorganisms called ... oxidize ammonia, according to an international team of researchers ... , Soil microbes, in a process ... nitrates, which are used as nutrients by plants. , ...
... the sequencing of the chimpanzee genome last year, geneticists have ... our closest evolutionary relative, looking for the differences that distinguish ... the human DNA sequence with the most dramatically increased rate ... is still unknown, but it appears to be directly involved ...
... estimates, hepatitis has become a worldwide health problem, ... abroad. Researchers are experimenting with combinations of ... In research presented today at Digestive Disease ... making significant progress to improve symptoms of the ...
Cached Biology News:Ammonia-loving archaea win landslide majority 2Ammonia-loving archaea win landslide majority 3Researchers identify human DNA on the fast track 2Researchers identify human DNA on the fast track 3Novel therapy combinations gain ground in treating hepatitis 2Novel therapy combinations gain ground in treating hepatitis 3Novel therapy combinations gain ground in treating hepatitis 4Novel therapy combinations gain ground in treating hepatitis 5Novel therapy combinations gain ground in treating hepatitis 6
Rabbit polyclonal to NCoR2, prediluted ( Abpromise for all tested applications). entrezGeneID: 9612 SwissProtID: Q9Y618...
...
... Anti-Clusterin α chain (human), clone 41D ... Immunogen : Native clusterin purified ... pH 7.4, 0.15M NaCl and 0.05% ... on RIPA lysates from HeLa cells ...
Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Biology Products: